Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.81 |
| ▸ | MEN1 | O00255 | 6/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.81 |
| ▸ | RAB9A | P51151 | 6/20 | 0.81 |
| ▸ | TP53 | P04637 | 5/20 | 0.81 |
| ▸ | HPGD | P15428 | 5/20 | 0.81 |
| ▸ | NPC1 | O15118 | 5/20 | 0.81 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.81 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.81 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.81 |
| ▸ | POLB | P06746 | 3/20 | 0.81 |
| ▸ | TSHR | P16473 | 3/20 | 0.81 |
| ▸ | EGFR | P00533 | 3/20 | 0.81 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.81 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13640743 | 0.90 | MEN1 (0.65) | MAPTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Genistein SCHEMBL29352944 | 0.90 | MAPT (1.00) | MAPTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Genistein SCHEMBL19166 | 0.90 | MAPT (1.00) | MAPTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Genistein SCHEMBL554056 | 0.90 | MAPT (1.00) | MAPTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Genistein SCHEMBL551801 | 0.88 | MAPT (0.97) | MAPTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Genistein SCHEMBL38650814 | 0.88 | MAPT (0.97) | MAPTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Genistein SCHEMBL31168045 | 0.88 | MAPT (0.97) | MAPTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Genistein SCHEMBL551352 | 0.88 | MAPT (0.97) | MAPTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Genistein SCHEMBL551402 | 0.88 | MAPT (0.97) | MAPTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Genistein SCHEMBL551449 | 0.88 | MAPT (0.97) | MAPTMEN1KMT2ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230200388-A1 | COMPOUNDS AND METHODS FOR STIMULATING PLANTS | Sound Agriculture Company (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20180185303-A1 | MONOAMINE OXIDASE INHIBITORS AND METHODS FOR TREATMENT AND DIAGNOSIS OF PROSTATE CANCER | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2018-07-05 | — | — | US | disclosed |
| US-9974766-B2 | Prenylated isoflavones for treatment of subjects with multidrug-resistant cancer | MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (MO) | 2018-05-22 | — | — | US | disclosed |
| US-9783592-B2 | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-10-10 | — | — | US | disclosed |
| WO-2017090007-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF UREA CYCLE DISORDERS AND HEPATIC DISEASES | RAO M SURYA (IN) | 2017-06-01 | — | — | WO | disclosed |
| US-20170151212-A1 | PRENYLATED ISOFLAVONES FOR TREATMENT OF SUBJECTS WITH MULTIDRUG-RESISTANT CANCER | MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2017-06-01 | — | — | US | disclosed |
| US-20170049793-A1 | MOLECULAR ACTIVATORS OF THE WNT/BETA-CATENIN PATHWAY | THE GENERAL HOSPITAL CORPORATION (US) | 2017-02-23 | — | — | US | disclosed |
| US-20160367693-A1 | Selective Arylation of Dichalcogenides in Biomolecules | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-22 | — | — | US | disclosed |
| US-9127088-B2 | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150152187-A1 | Anti-PSMA Antibodies Conjugated to Nuclear Receptor Ligand Polypeptides | AMBRX, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20140187510-A1 | MOLECULAR ACTIVATORS OF THE WNT/BETA-CATENIN PATHWAY | THE GENERAL HOSPITAL CORPORATION (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140073611-A1 | METHODS FOR DRUG SCREEN USING ZEBRAFISH MODEL AND THE COMPOUNDS SCREENED THEREFROM | NATIONAL TAIWAN UNIVERSITY (TW) | 2014-03-13 | — | — | US | disclosed |
| US-20130123178-A1 | GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2013-05-16 | — | — | US | disclosed |
| US-20120283313-A1 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS | NORTHWESTERN UNIVERSITY (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120046242-A1 | MOLECULAR ACTIVATORS OF THE WNT/BETA-CATENIN PATHWAY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-02-23 | — | — | US | disclosed |
| US-20110262482-A1 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20070037875-A1 | Genistein inhibition of transthyretin amyloidosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-02-15 | — | — | US | disclosed |
| US-4117149-A | 4-OXO-4H-BENZOPYRANS AS ANIMAL GROWTH PROMOTANTS | PFIZER INC. (US) | 1978-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046242-A1 | MOLECULAR ACTIVATORS OF THE WNT/BETA-CATENIN PATHWAY | WNT1, CTNNB1, WNT3A | MAPT 2364/4885MEN1 4099/4885KMT2A 3873/4885 |
| US-20110262482-A1 | ANTI-VIRAL COMPOUNDS | MAVS, EIF2AK2, IRF3 | MAPT 3520/4885MEN1 4873/4885KMT2A 3571/4885 |
| US-20150152187-A1 | Anti-PSMA Antibodies Conjugated to Nuclear Receptor Ligand Polypeptides | AR, PSMA1, NR2E3 | MAPT 1286/4885MEN1 689/4885KMT2A 1416/4885 |
| US-20170151212-A1 | PRENYLATED ISOFLAVONES FOR TREATMENT OF SUBJECTS WITH MULTIDRUG-RESISTANT CANCER | ABCB1, ABCC1, ABCB11 | MAPT 4795/4885MEN1 2461/4885KMT2A 3183/4885 |
| US-20160367693-A1 | Selective Arylation of Dichalcogenides in Biomolecules | SCLY, SELENOI, TPO | MAPT 4521/4885MEN1 1132/4885KMT2A 3830/4885 |
| US-20180185303-A1 | MONOAMINE OXIDASE INHIBITORS AND METHODS FOR TREATMENT AND DIAGNOSIS OF PROSTATE CANCER | MAOA, COMT, MAOB | MAPT 592/4885MEN1 2198/4885KMT2A 444/4885 |
| US-20070037875-A1 | Genistein inhibition of transthyretin amyloidosis | TTR, SHBG, TTPA | MAPT 90/4885MEN1 1444/4885KMT2A 4252/4885 |
| US-20120283313-A1 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS | MAPK4, MAP4K4, MAP3K4 | MAPT 2493/4885MEN1 302/4885KMT2A 772/4885 |
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | COASY, JMJD7, PTMS | MAPT 3572/4885MEN1 3675/4885KMT2A 2272/4885 |
| US-20130123178-A1 | GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY | GIPR, GLP1R, GCGR | MAPT 4294/4885MEN1 3189/4885KMT2A 3131/4885 |
| US-20140073611-A1 | METHODS FOR DRUG SCREEN USING ZEBRAFISH MODEL AND THE COMPOUNDS SCREENED THEREFROM | PLOD3, MYOC, SLTM | MAPT 2354/4885MEN1 4287/4885KMT2A 3355/4885 |
| US-20140187510-A1 | MOLECULAR ACTIVATORS OF THE WNT/BETA-CATENIN PATHWAY | WNT1, CTNNB1, WNT3A | MAPT 2364/4885MEN1 4099/4885KMT2A 3873/4885 |
| US-20230200388-A1 | COMPOUNDS AND METHODS FOR STIMULATING PLANTS | SNRK, GRK1, PPIP5K2 | MAPT 4278/4885MEN1 3498/4885KMT2A 3582/4885 |
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | ERBB2, ACP1, TK1 | MAPT 3770/4885MEN1 3627/4885KMT2A 1636/4885 |
| US-20170049793-A1 | MOLECULAR ACTIVATORS OF THE WNT/BETA-CATENIN PATHWAY | WNT1, CTNNB1, WNT3A | MAPT 2364/4885MEN1 4099/4885KMT2A 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.